⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Form 8-K
sec.gov
CTOR
CTXR
Form 8-K
sec.gov
CTXR
CTOR
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
Form 8-K
sec.gov
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
prnewswire.com
CTXR
CTOR
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
prnewswire.com
CTXR
CTOR